Price Alert

Dyne Therapeutics Inc. (DYN)

NASDAQ: DYN · Real-Time Price · USD

13.06

0.51 (4.06%)

At close: Oct 03, 2025, 3:59 PM

13.25

1.45%

After-hours: Oct 03, 2025, 07:11 PM EDT

4.06% (1D)

Bid	11.51
Market Cap	1.86B
Revenue (ttm)	1.57M
Net Income (ttm)	-412.88M
EPS (ttm)	-3.83
PE Ratio (ttm)	-3.41
Forward PE	-4.02
Analyst	Buy
Dividends	n/a

Ask	13.83
Volume	1,256,470
Avg. Volume (20D)	2,960,740
Open	12.62
Previous Close	12.55
Day's Range	12.62 - 13.11
52-Week Range	6.36 - 35.90
Beta	1.08
Ex-Dividend Date	n/a

About DYN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DYN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DYN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+3.34%

Dyne Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

2 months ago

+7.72%

Dyne Therapeutics shares are trading higher on possible continued strength after the company reported Q2 financial results on Monday.

News

3 weeks ago · seekingalpha.com

Dyne Therapeutics, Inc. (DYN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Dyne Therapeutics, Inc. (NASDAQ:DYN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants John Cox - CEO, President & Director Erick Lucera - CFO...

2 months ago · zacks.com

Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?

The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon...

2 months ago · benzinga.com

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Dyne Therapeutics Inc DYN reported a loss for the second quarter on Monday.

2 months ago · fool.com

Dyne Reports Wider Loss in Fiscal Q2

2 months ago · businesswire.com

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatm...